 |
市場調査レポート
商品コード
1373785
消化性潰瘍治療薬の世界市場 (2023-2030年)：タイプ (プロトンポンプ阻害薬 (PPI)・ヒスタミンH2受容体拮抗薬) 別の規模・シェア・成長分析・予測Global Peptic Ulcer Drugs Market Size, Share, Growth Analysis, By Type(Proton pump inhibitors (PPIs), histamine H2-receptor antagonists) - Industry Forecast 2023-2030 |
||||||
| 消化性潰瘍治療薬の世界市場 (2023-2030年)：タイプ (プロトンポンプ阻害薬 (PPI)・ヒスタミンH2受容体拮抗薬) 別の規模・シェア・成長分析・予測 |
|
出版日: 2023年10月14日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
消化性潰瘍治療薬の市場規模は、2021年の44億米ドル、2022年の46億米ドルから、予測期間中は3.5%のCAGRで推移し、2030年には64億米ドルの規模に成長すると予測されています。
消化性潰瘍治療薬の市場は、いくつかの要因によって着実な成長を遂げています。消化性潰瘍疾患は、世界で数百万人が罹患する一般的な胃腸疾患であり、同市場は消化性潰瘍疾患の有病率の増加、高齢化人口の増加、喫煙や飲酒などの不健康な生活習慣の増加によって牽引されています。
また、医療技術の進歩や革新的な製剤の開発も市場の成長に寄与しています。しかし一方で、ジェネリック医薬品のアベイラビリティや代替治療オプションの出現といった要因が、市場に課題を突きつけています。それにもかかわらず、消化性潰瘍の早期診断と効果的な治療の重要性に対する認識が高まっていることから、市場は成長が期待されています。
消化性潰瘍治療薬市場における主要動向の1つに、好まれる選択肢としてのプロトンポンプ阻害薬 (PPI) の採用の増加があります。この動向は、他の薬剤クラスと比較した場合のPPIの優れた有効性・安全性プロファイルによってもたらされています。PPIは長期間にわたって症状を緩和し、胃酸の分泌を抑えることで潰瘍の治癒を助けます。さらに、製剤の進歩により、PPIのバイオアベイラビリティと患者のコンプライアンスが改善されています。PPIへの嗜好の高まりは、消化性潰瘍治療薬の需要を促進すると予想されています。
当レポートでは、世界の消化性潰瘍治療薬の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
- エグゼクティブサマリー
- 調査手法
- 親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 主要な市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要な成功要因
- 競合の程度
- 市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 市場力学
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
- 世界の消化性潰瘍治療薬市場：タイプ別
- 市場概要
- プロトンポンプ阻害薬 (PPI)
- ヒスタミンH2受容体拮抗薬
- 制酸薬
- 抗生物質
- 世界の消化性潰瘍治療薬市場：地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
- 競合情勢
- トップ5社の比較
- 主要企業の市場での位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
- 主要企業プロファイル
- MedicoPharm Ltd.
- Pharmanova Inc.
- Gastrotech Pharmaceuticals
- BioCure Pharmaceuticals
- Medix Corporation
- PharmaPro Industries
- Ulcerex Pharma
- GastroMed Solutions
- Digesta Pharmaceuticals
- Healix Pharmaceuticals
- Pepto Therapeutics
- Gastronex Ltd.
- DigestCare Pharmaceuticals
- Ulcera Pharmaceuticals
- GastroCure Inc.
- Stomax Pharmaceuticals
- Digestive Health Solutions
- MedicoDigest
- Gastropedia Pharmaceuticals
- GastroGenix Corporation
Peptic Ulcer Drugs Market size was valued at USD 4.4 billion in 2021 and is poised to grow from USD 4.6 billion in 2022 to USD 6.4 billion by 2030, growing at a CAGR of 3.5% in the forecast period (2023-2030).
The global peptic ulcer drugs market is witnessing steady growth due to several factors. Peptic ulcer disease is a common gastrointestinal disorder that affects millions of people worldwide. The market for peptic ulcer drugs is driven by the increasing prevalence of peptic ulcer disease, the growing aging population, and the rising adoption of unhealthy lifestyle habits such as smoking and alcohol consumption.
Additionally, advancements in medical technology and the development of innovative drug formulations have contributed to the growth of the market. However, factors such as the availability of generic drugs and the emergence of alternative treatment options pose challenges to the market. Nonetheless, the increasing awareness about the importance of early diagnosis and effective treatment of peptic ulcers is expected to drive the market forward.
Top-down and bottom-up approaches were used to estimate and validate the size of the global Peptic Ulcer Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Peptic Ulcer Drugs Market Segmental Analysis
The global peptic ulcer drugs market is segmented by type and region. Based on type, the market can be segmented into proton pump inhibitors (PPIs), histamine H2-receptor antagonists, antacids, and antibiotics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Peptic Ulcer Drugs Market Drivers
Increasing Prevalence Of Peptic Ulcers Worldwide
- One driver of the global peptic ulcer drugs market is the increasing prevalence of peptic ulcers worldwide. Peptic ulcers are a common gastrointestinal disorder affecting millions of people, and the demand for effective treatment options is growing. Factors such as unhealthy lifestyles, stress, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) contribute to the rising incidence of peptic ulcers. This drives the demand for peptic ulcer drugs, leading to market growth.
Peptic Ulcer Drugs Market Restraints
Availability Of Alternative Treatment Options
- One restraint of the global peptic ulcer drugs market is the availability of alternative treatment options. In addition to pharmaceutical drugs, there are non-pharmacological approaches such as lifestyle modifications, dietary changes, and natural remedies that are considered effective in managing peptic ulcers. Some individuals may prefer these alternatives, which can impact the demand for traditional peptic ulcer drugs. Moreover, the potential side effects and risks associated with long-term medication use may also lead to concerns among patients and healthcare providers, influencing the market dynamics.
Competitive Landscape for Global Peptic Ulcer Drugs Market
The global peptic ulcer drugs market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of Peptic Ulcer Drugs. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions.
Market Trends of Global Peptic Ulcer Drugs Key
- One key market trend in the global peptic ulcer drugs market is the increasing adoption of proton pump inhibitors (PPIs) as a preferred treatment option. PPIs are a class of drugs that reduce the production of stomach acid and provide effective relief from peptic ulcers. The trend is driven by the superior efficacy and safety profile of PPIs compared to other drug classes. PPIs offer long-lasting symptom relief and help in healing the ulcers by reducing acid production. Additionally, advancements in drug formulations have improved the bioavailability and patient compliance of PPIs. The growing preference for PPIs is expected to drive the demand for peptic ulcer drugs in the market.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Peptic Ulcer Drugs Market by Type
- Market Overview
- Proton pump inhibitors (PPIs)
- histamine H2-receptor antagonists
- antacids
- and antibiotics
- Global Peptic Ulcer Drugs Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- MedicoPharm Ltd. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmanova Inc. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gastrotech Pharmaceuticals (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioCure Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medix Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PharmaPro Industries (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ulcerex Pharma (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GastroMed Solutions (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Digesta Pharmaceuticals (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Healix Pharmaceuticals (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pepto Therapeutics (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gastronex Ltd. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DigestCare Pharmaceuticals (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ulcera Pharmaceuticals (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GastroCure Inc. (Brazil)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stomax Pharmaceuticals (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Digestive Health Solutions (Mexico)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MedicoDigest (Russia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gastropedia Pharmaceuticals (Argentina)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GastroGenix Corporation (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
